Tailor-made molecules for the drugs of tomorrow

Getting a drug to market is no easy feat, especially with tight regulations to comply with and the plethora of products that are already available. This is why a service that streamlines the discovery process and leads to improved outcomes during clinical trials for drug candidates is likely to be very desirable

picture of

Breaking News

Phoenix Molecular Designs announces manufacturing collaboration with WuXi STA

Phoenix Molecular Designs (PhoenixMD), a privately held biotechnology company designing precise cancer therapeutics by ...

Relocation reflects ambitious growth plans

Ingenza is pleased to announce its relocation to Roslin Innovation Centre, a £30 million, multipurpose research hub on ...

Rousselot and Peptan build on innovation days success to boost customer-first strategy

Leading producer of gelatin and collagen peptides, Rousselot, started 2018 with a strong focus on innovation, in line ...

Gene transfer therapy approved for the treatment of ALL: part II

In August 2017, Novartis received FDA approval for its chimeric antigen receptor T (CAR-T) cell therapy, Kymriah, for ...

Samdi Tech expands small molecule compound libraries through partnership with Enamine

SAMDI Tech, Inc., headquartered in Chicago (IL, USA) leads the industry with an innovative approach to drug discovery

Antimicrobial therapy can prevent sepsis in pneumonia patients

Research sheds light on initial phase of infectious disease and potential for prevention of pneumococcal septicaemia

Advances in medical technology

Overhauling operating models to create digital value

Crescendo Biologics reaches first major milestone in strategic collaboration with Takeda

Crescendo, the developer of multifunctional biologics, including targeted T-cell engagers, has achieved the first major ...

Sartorius Stedim Biotech and Penn State University announce partnership

Sartorius Stedim Biotech and Penn State University have entered into a collaborative partnership to advance ...

Regenerative medicine and the benefits of cell-based combinatorial screening technology

Although many technical challenges remain ahead, regenerative medicine has the potential to profoundly change the way ...

Inside Patheon’s new flexible pharmaceutical development facilities

In the pharmaceutical sector, flexible facilities are in demand as new niche therapies replace traditional blockbusters. ...

PhoreMost and Plexxikon collaborate to identify novel drug targets

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, has signed a ...

GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics

Agreement strengthens Orchard’s position as a global leader in gene therapy for rare diseases